# Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma

> **NCT01083602** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 55 (actual)

## Conditions studied

- Relapsed and Bortezomib Refractory Multiple Myeloma
- Refractory Multiple Myeloma
- Multiple Myeloma in Relapse

## Interventions

- **DRUG:** panobinostat
- **DRUG:** bortezomib
- **DRUG:** dexamethasone

## Key facts

- **NCT ID:** NCT01083602
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2014-02
- **Final completion:** 2014-02
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2017-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01083602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01083602, "Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01083602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*